Small
Cell Lung Cancer Treatment
Professional Information |
 |
|
|
Staging procedures are important in distinguishing patients who have
disease limited to their thorax from those who have distant metastases.
Determining the stage of cancer by nonsurgical means allows a better
assessment of prognosis and identifies sites of tumor that can be evaluated
for response. Also, the choice of treatment is usually influenced by stage,
particularly when chest irradiation or surgical excision is added to
chemotherapy for patients with limited stage disease. Staging procedures
commonly used to document distant metastases include bone marrow
examination, computed tomographic or magnetic resonance imaging scans of the
brain, computerized tomographic scans of the chest and the abdomen, and
radionuclide bone scans.
Because occult or overt metastatic disease is present at diagnosis in
most patients, survival is usually not affected by small differences in the
amount of locoregional tumor involvement. Therefore, the detailed TNM
staging system developed for lung cancer by the American Joint Committee on
Cancer (AJCC) is not commonly employed in patients with small cell
carcinoma. This international staging system is outlined in detail in the
PDQ summary on non- small cell lung cancer. A simple 2-stage system
developed by the Veterans Administration Lung Cancer Study Group is more
commonly used for staging small cell lung cancer patients.1
Limited stage small cell lung cancer means tumor confined to the
hemithorax of origin, the mediastinum, and the supraclavicular nodes, which
can be encompassed within a "tolerable" radiation therapy port.
There is no universally accepted definition of this term, and patients with
pleural effusion, massive pulmonary tumor, and contralateral supraclavicular
nodes have been both included within and excluded from limited stage by
various groups.
Extensive stage small cell lung cancer means tumor that is too widespread
to be included within the definition of limited stage disease above.
Patients with distant metastases (M1) are always considered to have
extensive stage disease.1,2
References:
- Zelen
M: Keynote address on biostatistics and data retrieval. Cancer
Chemotherapy Reports 4(2): 31-42, 1973.
- Mountain
CF: Revisions in the International System for Staging Lung Cancer. Chest
111(6): 1710-1717, 1997.
Back to Content Page
Next >>
|